Amendments to the Claims:

1-70. (Cancelled)

71. (New) A hybridoma cell line deposited as ATCC Accession Number PTA-5704.

72. (New) An antibody produced by the hybridoma cell line of claim 71.

73. (New) The antibody of claim 72, wherein the antibody is an antibody fragment.

74. (New) The antibody of claim 73, wherein the antibody fragment is selected from the group consisting of Fab, Fab', $F(ab')_2$, Fv fragments, rIgG, diabodies, single chain antibodies, and multispecific antibodies.

75. (New) The antibody of claim 72, wherein the antibody is conjugated to an effector moiety.

76. (New) The antibody of claim 75, wherein the effector moiety is selected from the group consisting of: a fluorescent label, a radioisotope and a cytotoxic agent.

77. (New) The antibody of claim 76, wherein the cytotoxic agent is selected from the group consisting of: diphtheria A chain, exotoxin A chain, ricin A chain, abrin A chain, curcin, crotin, phenomycin, enomycin, and auristatin.

78. (New) The antibody of claim 77 wherein the cytotoxic agent is auristatin.

79. (New) The antibody of claim 76, wherein the radioisotope is selected from the group consisting of ^{3}H, ^{14}C, ^{32}P, ^{35}S, ^{125}I, ^{131}I, ^{90}Y and ^{186}Re.

80. (New) The antibody of claim 72 or 75, wherein the antibody binds a polypeptide having the amino acid sequence of SEQ ID NO:2.

81. (New) The antibody of claim 80, wherein the polypeptide is on a cancer cell.

82. (New) The antibody of claim 81, wherein the antibody inhibits growth of the cancer cell.

83. (New) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the antibody of claim 72.

84. (New) A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the antibody of claim 78.

85. (New) An antibody produced by a hybridoma cell line having ATCC Accession number PTA-5704.

86. (New) The antibody of claim 85, wherein the antibody is a monoclonal antibody.

87. (New) The antibody of claim 85, wherein the antibody is chimeric or humanized.